DR. KIRAN KUMAR

Dr.NEERAJA T G

Abstract

PURPOSE: To evaluate the efficacy of IFNα2b in the treatment of OSSN.

METHODS: This is a prospective, interventional study of 68 patients with histological proven OSSN. Patients were given subconjunctival perilesional injection of recombinant IFNα2b 3 million IU in 0.5 ml. Patients were followed up weekly until complete resolution.

RESULTS: 68 eyes (68 patients) that were treated with subconjunctival IFNα2b. Clinical resolution of tumor occurred in 95.6%(65/68) of cases. The median time for tumor resolution was 1.5 months (range 1- 3). In the time of follow-up there have been no treatment failures or recurrences. Systemic side effect that was encountered was post injection flu like illness for 2 days.

CONCLUSION: Interferons have emerged as a promising therapeutic modality for the treatment of OSSN. Subconjunctival/perilesional Interferon injection can be used as safe alternative to topical treatment. It has the advantage of better patient compliance with fewer local side effects.

Full Text